Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 3/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | TYMS | P04818 | 1/20 | 0.60 |
| ▸ | BCHE | P06276 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22943603 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL135209 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL17236294 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL4198253 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL17232081 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL12918450 | 1.00 | TK1 (0.69) | TK1POLBTYMSBCHE | |
| SCHEMBL8470853 | 0.91 | TK1 (0.64) | TK1POLBTYMSBCHE | |
| SCHEMBL7571044 | 0.91 | TK1 (0.66) | TK1POLBTYMSBCHE | |
| SCHEMBL4804983 | 0.91 | POLB (0.68) | TK1POLBTYMSBCHE | |
| SCHEMBL6379335 | 0.91 | POLB (0.68) | TK1POLBTYMSBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| CN-117343990-A | Method and kit for determining target polynucleotide and probe set | 牛津纳米孔科技公开有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | disclosed |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-05-11 | — | — | US | disclosed |
| EP-1385937-A1 | DELIVERY OF POLYNUCLEOTIDE AGENTS TO THE CENTRAL NERVOUS SYSSTEM | CHIRON CORPORATION (US) | 2004-02-04 | — | — | EP | disclosed |
| US-6677445-B1 | INCLUDING 5'-O-ALKYL NUCLEOTIDE, TWO BLOCKS OF SEVEN TO TWELVE PHOSPHODIESTER-LINKED 2'-O-ALKYL RIBONUCLEOTIDES, BLOCK OF FIVE TO TWELVE PHOSPHOROTHIOATE-LINKED DEOXYRIBONUCLEOTIDES, AND GROUP WHICH BLOCKS NUCLEASE ACTIVITY AT 3' END | CHIRON CORPORATION | 2004-01-13 | — | — | US | disclosed |
| EP-1373286-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030165434-A1 | Delivery of polynucleotide agents to the central nervous system | CHIRON CORPORATION | 2003-09-04 | — | — | US | disclosed |
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-06-26 | — | — | US | disclosed |
| WO-2002086105-A1 | DELIVERY OF POLYNUCLEOTIDE AGENTS TO THE CENTRAL NERVOUS SYSSTEM | CHIRON CORPORATION (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002072791-A2 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORT | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2002-09-19 | — | — | WO | disclosed |
| US-20010044528-A1 | Chimeric antisense oligonucleotides and cell transfecting formulations thereof | INNIS MICHAEL A (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1144609-A2 | CHIMERIC ANTISENSE OLIGONUCLEOTIDES AND CELL TRANSFECTING FORMULATIONS THEREOF | CHIRON CORPORATION (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2001016306-A2 | CHIMERIC ANTISENSE OLIGONUCLEOTIDES AND CELL TRANSFECTING FORMULATIONS THEREOF | CHIRON CORPORATION (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030120035-A1 | Linkers and co-coupling agents for optimization of oligonucleotide synthesis and purification on solid supports | PCNA, LIG4, DCLRE1A | TK1 282/4885POLB 16/4885TYMS 222/4885 |
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885POLB 4/4885TYMS 273/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885POLB 12/4885TYMS 179/4885 |
| US-20230148152-A1 | METHOD OF SYNTHESIZING SINGLE-STRANDED NUCLEOTIDE SEQUENCE, BLOCKED NUCLEOSIDE TRIPHOSPHATES AND RELATED METHODS | RNGTT, NT5C3B, TYMP | TK1 58/4885POLB 4/4885TYMS 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.